{"id":"de-104-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":"null","effect":"Eye irritation"}]},"_chembl":{"chemblId":"CHEMBL3545153","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the production of pro-inflammatory cytokines, thereby reducing the severity of ocular inflammation. This is achieved through its mechanism of action, which is not fully elucidated. Further research is needed to fully understand its mechanism of action.","oneSentence":"DE-104 ophthalmic solution is an anti-inflammatory agent that reduces inflammation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:37.589Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of non-infectious uveitis affecting the posterior segment of the eye"}]},"trialDetails":[{"nctId":"NCT00868894","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2009-03","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":49},{"nctId":"NCT00650338","phase":"PHASE2","title":"Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-03","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":165},{"nctId":"NCT00656240","phase":"PHASE2","title":"To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT00657579","phase":"PHASE2","title":"Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1907,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DE-104 ophthalmic solution","genericName":"DE-104 ophthalmic solution","companyName":"Santen Pharmaceutical Co., Ltd.","companyId":"santen-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DE-104 ophthalmic solution is an anti-inflammatory agent that reduces inflammation in the eye. Used for Treatment of non-infectious uveitis affecting the posterior segment of the eye.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}